Neuroblastoma (NB) is a pediatric tumor of neural crest origin with heterogeneous phenotypes. Although low-stage tumors carry a favorable prognosis, 450% of high-risk NB relapses after treatment with a fatal outcome. Thus developing therapies targeting refractory NB remains an unsolved clinical problem. Brain-derived neurotrophic factor (BDNF) and its TrkB receptor are known to protect NB cells from chemotherapy-induced cell death, while neuropeptide Y (NPY), acting via its Y2 receptor (Y2R), is an autocrine proliferative and angiogenic factor crucial for maintaining NB tumor growth. Here we show that in NB cells, BDNF stimulates the synthesis of NPY and induces expression of another one of its receptors, Y5R. In human NB tissues, the expression of NPY and Y5R positively correlated with the expression of BDNF and TrkB. Functionally, BDNF triggered Y5R internalization in NB cells, whereas Y5R antagonist inhibited BDNF-induced p44/42 mitogen-activated protein kinase activation and its pro-survival activity. These observations suggested TrkB-Y5R transactivation that resulted in cross-talk between their signaling pathways. Additionally, NPY and Y5R were upregulated in a BDNF-independent manner in NB cells under pro-apoptotic conditions, such as serum deprivation and chemotherapy, as well as in cell lines and tissues derived from posttreatment NB tumors. Blocking Y5R in chemoresistant NB cells rich in this receptor sensitized them to chemotherapy-induced apoptosis and inhibited their growth in vivo by augmenting cell death. In summary, the NPY/Y5R axis is an inducible survival pathway activated in NB by BDNF or cellular stress. Upon such activation, Y5R augments the pro-survival effect of BDNF via its interactions with TrkB receptor and exerts an additional BDNFindependent anti-apoptotic effect, both of which contribute to NB chemoresistance. Therefore, the NPY/Y5R pathway may become a novel therapeutic target for patients with refractory NB, thus far an incurable form of this disease.
INTRODUCTION
Neuroblastoma (NB) is a pediatric malignancy with heterogeneous phenotypes. 1 Although low-stage NB carries a favorable prognosis, 50-60% of high-risk tumors relapse with a fatal outcome. 2, 3 At present, there is no adequate therapy for refractory NB, and the mechanisms underlying its chemoresistance are poorly understood.
NB develops from precursors of sympathetic neurons, and the level of neuronal differentiation is one of the major factors determining its clinical behavior, with undifferentiated tumors being the most aggressive. 2, 4, 5 These tumors express neuronal markers and respond to factors regulating neuronal functions, such as brain-derived neurotrophic factor (BDNF) and its receptor tyrosine kinase (RTK), TrkB. 6, 7 BDNF is known for its neuroprotective effects. [8] [9] [10] In NB, BDNF is often endogenously expressed and acts as a pro-survival factor, enhancing resistance of these tumors to chemotherapy. [11] [12] [13] [14] These chemoresistance effects are mediated by the PI3K/Akt and p44/42 mitogen-activated protein kinase (MAPK) pathways. [8] [9] [10] [11] [12] [13] [14] Consistently, a high level of TrkB in NB tumors is an adverse prognostic factor. 7, [15] [16] [17] [18] Paradoxically, expression of TrkB in cell lines derived from advanced NBs is low or non-detectable. 17 Therefore NB cells stably transfected with TrkB are commonly used to study the role of BDNF in these tumors.
stimulates NPY expression in neuronal cells. [32] [33] [34] [35] [36] [37] Thus the goal of this study was to determine the molecular and functional interactions between BDNF and NPY systems in NB and their role in the biology of these tumors. We demonstrated that BDNF, acting via TrkB receptor, stimulates the expression of NPY and its Y5R. This, in turn, facilitates cross-talk between TrkB and Y5R signaling pathways, which then enhances pro-survival activity of BDNF. In addition to this BDNF-induced activation, NPY and Y5R are also upregulated in NB cells undergoing cellular stress, such as chemotherapy, and are highly expressed in cell lines and tissues derived from posttreatment patients. Such activation of the NPY/ Y5R axis enhances NB cell survival while blocking Y5R sensitizes them to chemotherapy. Taken together, we provide the first evidence for Y5R acting as an inducible pro-survival factor in NB, contributing to their chemoresistance.
RESULTS
BDNF stimulates NPY system expression in NB Given the low TrkB expression in NB cell lines, SH-SY5Y NB cells stably transfected with TrkB (SY5Y/TrkB) were used to determine interactions between NPY and BDNF systems. 11, 17 NPY release was elevated in SY5Y/TrkB cells, as compared with non-transfected SH-SY5Y cells (Figure 1a ), suggesting a TrkB-mediated stimulatory effect of endogenous BDNF on NPY expression. Indeed, in SY5Y/ TrkB cells, BDNF increased NPY and Y5R mRNA but not Y2R mRNA ( Figure 1b) . The selective increase in Y5R expression induced by BDNF was confirmed on a protein level by western blotting (Figure 1c ). Trk inhibitor K252a blocked these stimulatory effects of BDNF on NPY and Y5R expression (Figures 1b and c) . No further increase in NPY release was detected in BDNF-treated SY5Y/TrkB cells, suggesting saturation of the system by endogenous neurotrophin.
A similar stimulatory effect of BDNF on NPY system expression was observed in native NB cells. Despite a lower expression of TrkB receptor, non-transfected NB cells remained responsive to its ligand, as measured by BDNF-induced p44/42 MAPK phosphorylation (Supplementary Figure S1) . Consequently, BDNF increased NPY and Y5R mRNA in SK-N-BE(2) NB cells, and Trk antagonist blocked this effect (Figure 1d ). These increases in mRNA resulted in elevated NPY release and Y5R protein levels in BDNF-treated SK-N-BE(2) cells (Figures 1e and f) . To confirm this effect, we used a panel of NB cell lines derived from patients before (CHLA-15, SMS-KCN, SMS-KAN) and after chemotherapy (SK-N-BE(2), CHLA--20, SMS-KCNR, SMS-KANR). 38 Interestingly, the BDNF-induced Y5R upregulation was observed in posttreatment cell lines, whereas no such effect was detected in cells derived from patients at diagnosis (Figure 1g ).
In human NB tumors, expression of BDNF and NPY systems positively correlate with each other mRNA of NPY and BDNF systems were measured by real-time reverse transcriptase-PCR (RT-PCR) in 75 samples of NB tissues at diagnosis, a cohort enriched in undifferentiated and poorly differentiated tumors. These tumor subtypes typically carry a worse prognosis and are subsequently treated with chemotherapy. NPY and Y2R mRNA were present in all samples, while Y5R mRNA was detectable in 84% of cases. As summarized in Table 1 , significant correlations were detected by the Pearson's coefficient between BDNF and NPY systems, yet the magnitude and statistical significance of these correlations were dependent on NB differentiation. NPY mRNA had significant positive correlations with mRNA for both TrkB and BDNF when all NB cases were analyzed together. Among NB subtypes, a statistically significant correlation between NPY and TrkB mRNAs was observed in undifferentiated tumors, while a correlation between NPY and BDNF mRNAs achieved statistical significance in differentiating NBs. Correlations between Y5R expression and TrkB and BDNF mRNA levels were statistically significant in poorly differentiated tumors. Similarly, a significant association was observed between Y5R and BDNF mRNA levels in differentiating tumors. This translated to a statistically significant correlation between these two factors in all NB cases. No statistically significant correlations between Y2R and BDNF system expression were observed.
BDNF triggers internalization of Y5R
There is growing evidence for RTK-GPCR transactivation. 39, 40 To determine whether coordinated expression of TrkB and Y5R results in such interactions, we transfected SY5Y/TrkB cells with Y5R cDNA fused to enhanced green fluorescent protein (EGFP) and used the internalization of Y5R-EGFP as a measure of its activation. Transfected cells were treated with BDNF, with or without Y5R and Trk antagonist, and Y5R-EGFP receptor internalization was monitored by time-lapse fluorescence microscopy. Within 2 min of BDNF stimulation, Y5R was recruited to the cell membrane and subsequently internalized, as observed 8 min after treatment (Figure 2a ). These changes were reflected by differences in the ratio of membrane/sub-membrane receptor fraction ( Figure 2b ). No significant changes in Y5R distribution were observed upon pretreatment with Y5R or Trk antagonist ( Figures  2a and b ) or in non-treated cells (data not shown). BDNF-induced internalization of Y5R was confirmed by immunoprecipitation of membrane proteins. SY5Y/TrkB cells were treated with BDNF, and subsequently the surface proteins were biotinylated, immunoprecipitated and immunoblotted with anti-Y5R antibody. Within 8 min, BDNF triggered the decrease in the cell surface fraction of Y5R, whereas no statistically significant effect was observed upon pretreatment with Y5R or Trk antagonist (Figure 2c ).
Blocking Y5R interferes with BDNF-induced p44/42 MAPK signaling To determine whether TrkB-Y5R interactions result in signaling cross-talk, we tested the effects of their receptor antagonists on the activation of downstream pathways. In SY5Y/TrkB cells, NPY activated the p44/42 MAPK but not the Akt pathway (Figure 3a) . Y2R antagonist blocked NPY-driven p44/42 MAPK phosphorylation, whereas Y5R and Trk receptor antagonists had no effect. In contrast, BDNF-induced p44/42 MAPK activation was blocked by Trk inhibitor and significantly inhibited by Y5R antagonist, whereas Y2R antagonist had no effect (Figure 3a) . The BDNFinduced Akt activation was blocked by Trk inhibitor but remained unaffected by NPY receptor antagonists. These results were confirmed using NPY receptor siRNAs. Although both Y2R and Y5R siRNAs effectively inhibited their targets (Supplementary Figure S2) , only Y5R siRNA significantly decreased BDNF-induced p44/42 MAPK activation (Figure 3b) . Similarly, blocking Y5R reduced p44/42 MAPK phosphorylation triggered by BDNF in native SK-N-BE(2) cells (Figure 3c ), although no BDNF-induced Akt activation was observed (data not shown).
Y5R contributes to pro-survival effects of BDNF In SY5Y/TrkB cells cultured under low serum conditions, BDNF increased cell viability (Figure 4a ). This effect was decreased by Trk inhibitor, and further reduced by a combination of Trk and Y5R antagonists. Similarly, BDNF rescued NB cells from chemotherapyinduced cell death. For doxorubicin and vinblastine, the prosurvival effect of BDNF was significantly, yet partially, reduced by TrkB and Y5R antagonists alone, while treatment with combined antagonists was required for its complete blockage (Figure 4b , Supplementary Figure S3 ). In contrast, Trk inhibitor completely blocked the pro-survival activity of BDNF upon treatment with etoposide and cisplatin, while Y5R antagonist alone had no effect, suggesting the prevalence of a Y5R-independent Akt pathway. Nevertheless, in all cases, the combination of Trk and Y5R antagonist was the most effective and decreased the cell viability below control levels, indicating a contribution of endogenous BDNF and NPY to NB survival. These changes in cell viability were accompanied by corresponding changes in p44/42 MAPK activation (Figure 4b ).
The pro-survival effect of BDNF was also observed in native SK-N-BE(2) cells. Upon cisplatin treatment, BDNF increased cell viability and decreased caspase 3/7 activity, suggesting inhibition of apoptosis as the mechanism of its actions (Figure 4c ). The pro-survival effect of BDNF in SK-N-BE(2) cells treated with cisplatin and other chemotherapeutics was (2), CHLA-20, SMS-KCNR, SMS-KANR) was treated with BDNF, and Y5R expression was measured by western blotting, as above. The Y5R band intensities were quantified by densitometry (three independent experiments per cell line) and averaged for each group. In all the above experiments, cells were cultured in 1% FBS media for 24 h and then treated with BDNF (0.1-1 ng/ml) for 6-24 h, with our without TrkB antagonist K252a, at concentration 10
PS, unspecific protein stain. NPY system is activated in pro-apoptotic conditions Having determined TrkB-Y5R interactions, we sought to identify other factors activating Y5R in NB. To this end, SY5Y/TrkB cells were transfected with Y5R siRNA and cultured under various conditions. Upon 24 h culture in low serum media, Y5R siRNA had no effect on cell survival ( Figure 5a ). However, in cells subjected to more severe cellular stress, such as chemotherapy or serum deprivation for 48 h, Y5R knockdown significantly decreased cell viability. In line with these observations, Y5R protein was not detectable in SY5Y/TrkB cells cultured in 10% fetal bovine serum (FBS) media, while its expression was induced under serum-free conditions (Figure 5b ), implicating NPY/Y5R axis as an inducible pro-survival pathway.
Similarly, activation of the NPY/Y5R axis under cellular stress was observed in non-transfected NB cells expressing low levels of TrkB. In SK-N-BE(2) cells, chemotherapeutics increased mRNA of NPY and Y5R (Figure 5c ). Consequently, treatment with all compounds increased NPY release, which resulted in a significantly elevated NPY concentration in conditioned media from chemotherapy-treated SK-N-BE(2) cells (Figure 5d ). The increase in Y5R expression was confirmed by western blotting (Figure 5e ). Trk inhibitor did not block this effect, suggesting its BDNFindependent regulation (data not shown). As demonstrated for sensitivity to BDNF, the chemotherapy-induced increase in Y5R expression was detectable in a panel of cell lines derived from previously treated NB patients but not in pretreatment cells (Figure 5f ). 38 NPY exerts pro-survival effects in chemotherapy-treated NB cells Changes in the NPY system suggested its Y5R-mediated prosurvival activity. Indeed, in SK-N-BE(2) cells treated with various chemotherapeutics, NPY increased cell viability (Figure 6a ). Y5R antagonist blocked this effect and decreased NB cell survival below baseline, indicating a pro-survival effect of the endogenous peptide. The NPY-induced increase in cell viability was associated with reduced caspase 3/7 activity in chemotherapy-treated NB cells, suggesting the inhibition of apoptosis as the main mechanism of its action (Figure 6b ).
NPY system is upregulated in posttreatment NB cells To confirm the clinical relevance of NPY system activation observed upon short-term treatment, pairs of NB cell lines derived from patients before and after chemotherapy were compared in terms of NPY system expression. 38 On an mRNA level, the treatment-induced increase in NPY and Y5R expression was observed in CHLA-15/CHLA-20 and SMS-KCN/SMS-KCNR cell lines, while in the SMS-KAN/SMS-KANR pair, only Y5R mRNA was elevated (Figure 7a ). In line with the RT-PCR results, NPY cellular content was elevated in posttreatment CHLA-20 and SMS-KCNR but not SMS-KANR cells (Figure 7b ), while Y5R protein levels were increased in all posttreatment cells (Figure 7c ).
To validate findings in the cell lines, we compared Y5R immunostaining in primary NB tumors derived from non-treated patients and from those after chemotherapy. In non-treated tumors, Y5R expression was observed in single NB cells (an average 30% of positive tumor cells in undifferentiated and poorly differentiated NBs) (Figure 7d ). In contrast, in chemotherapytreated NB tumors, 100% of surviving NB cells was Y5R positive.
Blocking Y5R sensitizes NB cells to chemotherapy Chemotherapy-induced changes in NPY system expression suggested a role for Y5R in NB chemoresistance. To test the extent and specificity of this effect, we used CHLA-15 and CHLA-20 cells, a pair of pretreatment and posttreatment cell lines that are not only rich in Y5R but also express Y2R. 29 Cells were treated with increasing doses of chemotherapy in the presence of Y2R or Y5R antagonist. In both cell lines, blocking Y5R decreased cell viability, while Y2R inhibitor had no effect (Figure 8a ). These changes were associated with corresponding increases in caspase 3/7 activity upon Y5R but not Y2R antagonist treatment (Figure 8b ).
Y5R antagonist inhibits growth of chemoresistant NB cells in vivo
To validate the pro-survival effect of Y5R in vivo, subcutaneous xenografts obtained from chemoresistant CHLA-20 cells 38 were treated with Y5R antagonist. Blocking Y5R resulted in significant inhibition of CHLA-20 xenograft growth (Figure 8c) , which was associated with increased tumor cell death (Figure 8d) . No significant changes were observed in NB cell proliferation or tumor vascularization measured by Ki67 and von Willebrand factor (vWF) immunostaining, respectively (data not shown). . SY5Y/TrkB cells were cultured and treated with BDNF and Trk or Y5R antagonists, as above. Two hours after BDNF administration, cells were additionally treated with doxorubicin (1 μg/ml) or etoposide (2.75 μg/ml). Cell extracts for detection of activated p44/42 MAPK by western blotting were collected 1h later, while cell viability was measured by MTS assay 24 h later. (c) SK-N-BE(2) cells were cultured as described for panel (a), preincubated for 1 h with Trk or Y5R antagonists at concentrations 10 −6 M and then treated with BDNF (1 ng/ml) followed by cisplatin (0.5 μg/ml). Twenty-four hours later, cell viability was measured by MTS assay, and apoptosis was assessed by caspase 3/7 activity assay. DISCUSSION BDNF and NPY are important factors in NB biology. BDNF, acting via its TrkB receptor, promotes survival of chemotherapy-treated NB cells and stimulates their invasiveness and tumor angiogenesis. 6, 7, 41 Consequently, high expression of TrkB in tumor tissue correlates with poor prognosis in NB patients. 7, 15, 17 Similarly, elevated systemic levels of NPY are associated with a poor outcome of NB. [19] [20] [21] Actions of endogenous NPY mediated by its Y2R are essential to maintain NB cell proliferation and tumor vascularization. [19] [20] [21] 28, 29 However, functions of Y5R, which is also detectable in some NB cell lines, were not well defined. 28 Moreover, despite similar functions of NPY and BDNF, as well as a known stimulatory effect of BDNF on NPY synthesis in neurons, interactions of these two systems in NB remained unknown.
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Here we have shown that BDNF upregulates the NPY system in NB, which in turn enhances its pro-survival functions via interactions between TrkB and Y5R receptors.
In NB cells, BDNF increased synthesis of NPY and induced expression of its Y5R, whereas no consistent upregulation of Y2R was observed. These results are in agreement with the presence of binding sites for two transcription factors known to mediate neurotrophins' effects, AP-1 and CREB, in the promoters of NPY and Y5R but not Y2R. 42, 43 Importantly CREB is activated by p44/42 MAPK, the pathway previously shown to mediate BDNF-induced increase in NPY expression. 34, 43 The , CHLA-20, SMS-KCNR, SMS-KANR) was treated for 6-12 h with chemotherapeutic agents, as above, and Y5R was detected by western blotting. Expression levels from at least three independent experiments for each cell line were quantified by densitometry, and the results for all pretreatment and posttreatment cells were averaged. PS, unspecific protein staining.
NPY5R in neuroblastoma chemoresistance M Czarnecka et al enhanced responsiveness of posttreatment NB cells to BDNF stimulation could be associated with chemotherapy-induced overexpression of TrkB. We observed a trend toward increased TrkB expression in these cells, albeit not statistically significant (data not shown). The specificity of BDNF's stimulatory effect on the NPY system was confirmed by positive correlations between BDNF/TrkB and NPY/Y5R mRNAs, but not Y2R mRNA, as observed in human NB tissues. The strength of these correlations depended on tumor differentiation grade, which may be associated with the variability in TrkB and BDNF expression, as well as in the presence of stromal cells known to release BDNF and regulate NB growth. [44] [45] [46] Interestingly, the strongest associations of NPY and Y5R levels with the BDNF system expression were observed in different NB subsets, suggesting that other factors differentially expressed in these tumors modify BDNF actions. Importantly, NPY is highly expressed in all NB subtypes, while non-treated NBs express Y5R at much lower levels. 28, 29 Thus, Y5R expression rather than NPY level is the limiting factor for NPY/Y5R axis activation. Altogether, our data implicate NPY and Y5R, but not Y2R, as direct BDNF targets.
Expression of Y5R stimulated by BDNF resulted in TrkB-Y5R transactivation and signaling cross-talk, as demonstrated by Y5R internalization upon BDNF treatment and the decrease in BDNFinduced p44/42 MAPK activation while Y5R was blocked. Such RTK-GPCR transactivation has been shown for other receptors and often involves phosphorylation of GPCRs by RTKs or their signaling mediators, physical interactions between the receptors or simultaneous activation of p44/42 MAPK by both receptors. 39, 40, [47] [48] [49] [50] Further studies are required to determine which of these mechanisms mediate TrkB-Y5R interactions.
TrkB-Y5R transactivation enhanced BDNF-induced p44/42 MAPK phosphorylation and augmented its anti-apoptotic effect in chemotherapy-treated NB cells. However, these interactions did not affect the BDNF-activated PI3K/Akt pathway, suggesting its sole dependence on TrkB. Such a selective activation of signaling pathways is common for RTK-GPCR transactivation and may result from allosteric changes that occur due to receptor interactions. 49, [51] [52] [53] [54] Our results are in contrast to previous reports implicating the PI3K/Akt axis as the main pathway mediating pro-survival effects of BDNF in chemotherapy-treated NB cells. 11, 12, 14 However, the role of p44/42 MAPK in BDNF-induced survival has been demonstrated in paclitaxel-treated NB cells. 13 Similarly, in normal neurons, neuroprotective actions of BDNF and NPY are largely p44/42 MAPK mediated. [8] [9] [10] 30 Our results indicate that BDNF-induced p44/42 MAPK is dependent on TrkB-Y5R transactivation. Such RTK-GPCR interactions are regulated by RTK ligand and receptor availability. 40, 47, 55 In cells expressing high levels of RTKs or exposed to high concentrations of their ligand, no GPCR involvement is observed, and the signaling events solely depend on RTKs. In contrast, the RTK-GPCR cross-talk is activated in low concentrations of RTK and/or its agonist when the signal from RTK is not sufficient to trigger the biological response. In line with this, previous studies demonstrating PI3K/Akt pathway as solely responsible for BDNF's pro-survival effect relied on TrkB transfectants treated with high doses of neurotrophin (100 ng/ml), whereas markedly lower concentrations (0.1-1 ng/ml) were used in our study. 11, 12, 14 Moreover, we It also augments functions of the α1-adrenergic receptor in cardiomyocytes. 24, 58 Here we have shown that Y5R contributed to BDNF-induced, but not NPY-induced, p44/42 MAPK phosphorylation. This selectivity in Y5R signaling may depend on cellular context, such as the prevalence of Y2R expression, which binds the majority of NPY and/or high expression of TrkB, which recruits Y5R to its signaling complex.
Aside from BDNF-induced upregulation of the NPY/Y5R axis, expression of NPY and Y5R was increased under cellular stress, such as serum deprivation or chemotherapy. As seen with the response to BDNF, more pronounced upregulation of the NPY system was observed in cells derived from chemotherapy-treated NBs. This effect was not blocked by Trk inhibitor, suggesting BDNF-independent pro-survival activity of the NPY/Y5R pathway. Indeed, in chemotherapy-treated NB cells, NPY increased cell viability in a Y5R-dependent manner. Thus, while after short-term stimulation, such as that used to detect p44/42 MAPK activation, Y5R predominantly interacts with TrkB, under prolonged cellular stress it also mediates anti-apoptotic effects of NPY. Importantly, Y5R antagonist decreased the viability of chemotherapy-treated NB cells in the absence of exogenous survival factors, confirming the role of endogenous NPY and BDNF. The saturation of NPY receptors with the autocrine peptide may also explain the modest effect of exogenous NPY in these cells. The expression of two types of NPY receptors in NB-Y2R and Y5R-raises a question regarding the specificity of their functions. Previously, we have demonstrated that Y2R is constitutively expressed in NB cell lines and tumors, as well as in endothelium within tumor vasculature, and mediates proliferative and angiogenic actions of endogenous NPY. 28, 29 Here, we demonstrated that Y5R, but not Y2R, is an inducible, pro-survival NPY receptor. Altogether, our results indicate that actions of Y2R and Y5R in NB depend on the cellular context. During exponential growth, proliferative and pro-angiogenic actions of Y2R predominate (Figure 9a) . 28, 29 However, upon BDNF stimulation and under cellular stress, Y5R expression is induced and its TrkB-dependent and -independent pro-survival functions are activated, whereas Y2R does not have a major role (Figures 9b and c) . Ultimately, the effects of Y2R and Y5R antagonist on NB growth depend on the balance between tumor cell proliferation and apoptosis. Interestingly, despite their different biological functions, actions of both receptors are mediated by p44/42 MAPK. This could result not only from Y5R interactions with other receptors, which modify its function, but also from differences in Y2R and Y5R signaling, as Y2R regulates intracellular Ca ++ in addition to the decrease in cAMP stimulated by both receptors (Figure 9 ). 59, 60 The clinical relevance of Y5R activation was confirmed by its expression in all surviving NB cells within chemotherapy-treated tumors. This phenomenon may result from upregulation of Y5R in all tumor cells or selection of the Y5R-positive NB clones. In vivo, blocking Y5R increased apoptosis and inhibited growth of xenografts derived from Y5R-rich chemoresistant CHLA-20 cells. 38 This apoptotic effect was in agreement with increased caspase 3/7 activity observed in NB cells treated with Y5R antagonist in vitro. This is in contrast to anti-proliferative and anti-angiogenic effects of Y2R blockade, which also inhibit NB xenograft growth. 29 Thus our in vivo data corroborate the proliferative and pro-survival actions of Y2R and Y5R in NB, respectively. Although in the current study the xenografts were not treated with chemotherapy, cell death occurs in tumors naturally (for example, due to hypoxia). As shown in Ewing sarcoma, these conditions also upregulate Y5R. 61 Further studies are required to determine whether Y5R antagonists, alone or in combination with Y2R antagonist or Trk inhibitors, have a synergistic effect with chemotherapy in vivo. Importantly, Y5R antagonist has already been approved for clinical trials for other disorders. 62, 63 Overall, we present the first evidence for TrkB-Y5R interactions and their contribution to the anti-apoptotic effect of BDNF. We also demonstrate that Y5R, acting in a BDNF-dependent or -independent manner, is a pro-survival factor for NB cells, upregulated in pro-apoptotic conditions. Consequently, Y5R blockage increases NB cell death and sensitizes them to chemotherapy. These findings, along with our previous results implicating Y2R as a crucial proliferative and pro-angiogenic factor in NB, underscore the importance of the NPY system in NB biology and validate the peptide and its receptors as therapeutic targets. Importantly, while the NPY/Y2R axis is active in all NB tumors, implicating Y2R as a universal therapeutic target, Y5R may be the most relevant to chemoresistant, refractory NBs that lack an adequate treatment.
METHODS

Materials
Recombinant human BDNF was purchased from R&D Systems (Minneapolis, MN, USA); NPY from Bachem (San Carlos, CA, USA); Y5R antagonist, CGP71683, and Y2R antagonist, BIIE0246, from Tocris (Ellisville, MO, USA); and Trk inhibitor, K252a and chemotherapeutics from Sigma (St Louis, MO, USA).
Human NB samples mRNA and paraffin-embedded sections from 75 NB cases at diagnosis were obtained from Children's Oncology Group, while 4 paraffinembedded samples from NB tumors upon induction chemotherapy were collected by Dr Izycka-Swieszewska in compliance with institutional regulations. Use of these samples was approved by the Georgetown University Institutional Review Board.
Cell culture
Human NB cells SK-N-BE(2) and SH-SY5Y were obtained from ATCC (Manassas, VA, USA), SH-SY5Y cells stably transfected with TrkB cDNA (SY5Y/TrkB) from Dr Brodeur (University of Pennsylvania, Philadelphia, PA, USA) 11 and pairs of NB cell lines derived from patients at diagnosis and during induction chemotherapy-SMS-KCN and SMS-KCNR, SMS-KAN and SMS-KANR, CHLA-15 and CHLA-20-from Dr Reynolds (Children's Hospital of Los Angeles, CA, USA). 38 Cells were cultured according to the suppliers' recommendation.
Gene expression analyses
Real-time RT-PCR and NPY enzyme-linked immunosorbent assay were performed as previously described. 28, 64 Western blotting for NPY receptors was performed on membrane proteins isolated as previously described, 65 using goat polyclonal anti-Npy2r (My Biosource, Camarillo, CA, USA) and anti-Y5R (Everest Biotech, Ramona, CA, USA) antibodies, while unspecific . This effect is mediated by p44/42 MAPK and CREB. Expression of NPY and its Y5R is further upregulated under cellular stress, such as serum deprivation or chemotherapy, in a BDNF-independent manner. (c) Induction of Y5R expression in pro-apoptotic conditions activates its pro-survival actions. Upon BDNF stimulation, its receptor, TrkB, transactivates Y5R, which augments BDNF-induced p44/42 MAPK activation and its anti-apoptotic effect. TrkB-Y5R interactions do not affect BDNF-induced Akt activation. Y5R, acting via p44/42 MAPK, also mediates the pro-survival effect of NPY. This effect could be initiated by a decrease in cAMP levels, a signaling event triggered upon NPY/Y5R axis activation. Solid boxes, molecules tested in the current study; dashed boxes, unknown factors; no outline, molecules previously implicated in BDNF or NPY signaling in NB.
protein staining (Pierce Reversible Protein Stain Kit for Nitrocellulose Membranes, Thermo, Rockford, IL, USA) served as a loading control. Signaling molecules were detected in whole-cell extracts using the following antibodies: mouse monoclonal anti-phospho p44/42 E10, rabbit polyclonal anti-phospho Akt Thr308 and Ser473 (Cell Signaling Technology, Boston, MA, USA) and mouse monoclonal anti-β-actin (Sigma). Densitometry was conducted using the ImageJ software (National Institute of Health, Bethesda, MD, USA).
Y5R-EGFP transfections and live cell imaging
Human Y5R cDNA was cloned into pEGFP-N1 vector (Clontech Laboratories, Mountain View, CA, USA) and transfected into SY5Y/TrkB cells using Lipofectamine 2000 (Life Technologies, Grand Island, NY, USA). Transfected cells were imaged 24 h later with a Zeiss 510 LSM/META confocal microscope (Carl Zeiss AG, Jena, Germany) during 30-min incubation with BDNF (1 ng/ml), with or without 15-min preincubation with Y5R or Trk antagonist (10 −6 M). Fluorescence intensities on the cell membrane and in the sub-membrane areas were measured using the ImageJ software. For the analysis, multiple cellular regions with initial membrane Y5R-EGFP localization (membrane/sub-membrane fluorescence ratio ⩾ 1.3) were selected.
Cell surface protein immunoprecipitation SY5Y/TrkB cells were preincubated for 24 h in serum-free media and treated for 8 min with BDNF (1 ng/ml), with or without 15 min pretreatment with TrkB or Y5R antagonists (10 −6 M). Then cell surface proteins were biotynylated and immunoprecipitated using Cell Surface Protein Isolation Kit (Thermo Scientific, Rockford, IL, USA). Y5R in cell lysates and immunoprecipitation eluates were detected by western blotting.
Cell viability and apoptosis assays
Cells plated in 96-well plates were cultured in 1% FBS media for 24 h and treated as desired. After 24 h, the number of viable cells was measured using the MTS-based CellTiter 96 AQueous One Solution Cell Proliferation Assay, while caspase activity was measured using Apo-ONE Homogenous Caspase 3/7 reagent (Promega, Madison, W, USA).
siRNA transfection SY5Y/TrkB cells were transfected with 30 nM Y2R or negative control siRNA (Life Technologies), as previously described, 29 or with Y5R siGENOME SMART pool siRNA (Thermo Scientific) using Trans IT-TKO (Mirus, Madison, WI, USA). Forty-eight hours later, knockdown efficiency was tested by western blotting, while cell viability and signaling pathway activation were assessed as above.
NB xenografts
In all, 10 7 of CHLA-20 cells suspended in 0.1 ml of Matrigel (BD Biosciences, San Jose, CA, USA) were injected subcutaneously into the dorsal flank of 4-6-weeks-old female nude mice. When tumors reached a volume of 100 mm 3 , daily treatment with local injections of Y5R antagonist (10 −6 M, 0.1 ml) was initiated. Mice were euthanized once tumors reached a volume of approximately 1 cm 3 . This study was approved by an Institutional Animal Care and Use Committee of the Georgetown University.
Tissue analyses
Immunohistochemistry was performed using the following rabbit polyclonal antibodies: anti-Y5R (Novus Biologicals, LLC, Littleton, CO, USA), antiKi67 (Abcam, Cambridge, MA, USA) and anti-vWF (DAKO, Carpinteria, CA, USA). Cell death was detected by TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling; Roche, Indianapolis, IN, USA). All tissues were assessed by a pathologist. Staining area was quantified using the ImageJ software.
Statistical analysis
Statistical analyses were performed using the SigmaStat (Systat Software, Inc, San Jose, CA, USA), GraphPad (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS softwares (IBM Corporations, Armonk, NY, USA). Betweengroup comparisons were assessed using one-way or two-way repeated measures analysis of variance with post-hoc t-test, independent-samples t-tests or paired-samples t-tests, as appropriate. Significant associations were assessed at an alpha level of 0.05. All experiments were repeated at least three times. Data are presented as mean ± s.e. Bivariate associations are reported using the Pearson's product-moment correlation coefficient.
